Journal Articles

Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics. 2018 Oct 18;11:62-74. doi: 10.1016/j.omto.2018.10.001. PMID: 30505937; PMCID: PMC6249791.

Wedekind MF, Denton NL, Chen CY, Cripe TP. Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatr Drugs. 2018 Oct;20(5):395-408. doi: 10.1007/s40272-018-0297-x. PMID: 29948928; PMCID: PMC6153971.

Denton NL, Chen CY, Scott TR, Cripe TP. Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe? Biomedicines. 2016 Jul 7;4(3):13. doi: 10.3390/biomedicines4030013. PMID: 28536380; PMCID: PMC5344259.

Leddon JL, Chen CY, Currier MA, Wang PY, Jung FA, Denton NL, Cripe KM, Haworth KB, Arnold MA, Gross AC, Eubank TD, Goins WF, Glorioso JC, Cohen JB, Grandi P, Hildeman DA, Cripe TP. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Mol Ther Oncolytics. 2015 Jan 21;1:14010. doi: 10.1038/mto.2014.10. PMID: 27119100; PMCID: PMC4782947.

Friedman GK, Beierle EA, Gillespie GY, Markert JM, Waters AM, Chen CY, Denton NL, Haworth KB, Hutzen B, Leddon JL, Streby KA, Wang PY, Cripe TP. Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. Mol Ther Oncolytics. 2015;2:15016–. doi: 10.1038/mto.2015.16. Epub 2015 Sep 16. PMID: 26436134; PMCID: PMC4589754.

Cripe TP, Chen CY, Denton NL, Haworth KB, Hutzen B, Leddon JL, Streby KA, Wang PY, Markert JM, Waters AM, Gillespie GY, Beierle EA, Friedman GK. Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. Mol Ther Oncolytics. 2015;2:15015–. doi: 10.1038/mto.2015.15. Epub 2015 Sep 16. PMID: 26436135; PMCID: PMC4589755.

Wojton J, Meisen WH, Jacob NK, Thorne AH, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B. SapC- DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. Oncotarget. 2014 Oct 30;5(20):9703-9. doi: 10.18632/oncotarget.2232. PMID: 25210852; PMCID: PMC4259431.

Wojton J, Chu Z, Mathsyaraja H, Meisen WH, Denton N, Kwon CH, Chow LM, Palascak M, Franco R, Bourdeau T, Thornton S, Ostrowski MC, Kaur B, Qi X. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther. 2013 Aug;21(8):1517-25. doi: 10.1038/mt.2013.114. Epub 2013 Jun 4. PMID: 23732993; PMCID: PMC3734660.